Join the Sublocade group to help and get support from people like you.
Sublocade News
Buprenorphine for Opioid Use Disorder in Pregnancy Can Improve Outcomes
FRIDAY, May 2, 2025 – For mothers with opioid use disorder (OUD), treatment with buprenorphine in pregnancy is associated with improved maternal and infant outcomes, according to a study published...
Hospital Addiction Consultation Service Aids Opioid Use Disorder
WEDNESDAY, April 16, 2025 – A hospital-based addiction consultation service can improve receipt of evidence-based treatment for people with opioid use disorder (OUD), according to a study published...
Evidence Supports Continuing Buprenorphine for Acute Pain in Those With Opioid Use Disorder
MONDAY, March 31, 2025 – For patients with opioid use disorder (OUD), evidence supports continuation of buprenorphine during episodes of acute pain, but overall evidence for pain outcomes in these...
Indivior Announces FDA Approval of Label Changes for Sublocade (buprenorphine extended-release) Injection
Richmond, VA, February 24, 2025 – Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes f...
2017 to 2022 Saw Rise in ED Orders for Buprenorphine for Opioid Use Disorder
THURSDAY, Feb. 27, 2025 – Emergency clinicians in California increased prescription of buprenorphine for opioid use disorder (OUD) from 2017 to 2022, according to a study published online Feb. 19 in...
Mindfulness-Based Groups Tied to Significant Reduction in Opioid Craving
WEDNESDAY, Jan. 29, 2025 – For adults with opioid use disorder (OUD) receiving buprenorphine, a mindfulness-based group is similar to a recovery support group for opioid use, substance use, and...
2020 to 2023 Saw Increase in Buprenorphine Dispensing for Teens
THURSDAY, Dec. 26, 2024 – Buprenorphine dispensing increased among adolescents and decreased among young adults between 2020 and 2023, according to a research letter published online Dec. 23 in the...
Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone
FRIDAY, Oct. 18, 2024 – Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study...
Higher Buprenorphine Doses Reduce Acute Care for Opioid Use Disorder
WEDNESDAY, Oct. 2, 2024 – Higher doses of buprenorphine for patients with opioid use disorder (OUD) are associated with lower acute care utilization, according to a study published online Sept. 25...
Inmates in Many U.S. Jails Have No Access to Meds That Fight Opioid Addiction
TUESDAY, Sept. 24, 2024 – Opioid use disorder can be a contributing factor to Americans landing in the nation's prisons and jails, but those inmates typically have no access to medications that...
Socially, Economically Disadvantaged Communities Lack Access to Buprenorphine
FRIDAY, Aug. 23, 2024 – Restricted buprenorphine dispensing was most pronounced in socially and economically disadvantaged communities, according to a study published in the September issue of Drug ...
FDA Medwatch Alert: FDA Warns About Dental Problems with Buprenorphine Medicines Dissolved in the Mouth to Treat Opioid Use Disorder and Pain
What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the...
FDA Medwatch Alert: Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder - FDA Recommends Health Care Professionals Discuss Naloxone with All Patients when Prescribing
ISSUE: FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information....
FDA Approves Sublocade (buprenorphine) Once-Monthly Injection for Opioid Use Disorder
November 30, 2017 – The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use...
Further information
Related condition support groups
Opiate Dependence - Maintenance, Opiate Dependence